TITLE

Sign of Things to Come?

AUTHOR(S)
Houlton, Sarah
PUB. DATE
February 2006
SOURCE
Pharmaceutical Executive;Feb2006, Vol. 26 Issue 2, p50
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that the European Medicines Agency (EMEA) intends to complete its guidelines for the approval of generic copies of biologic medicines in early 2006. The approval of biogenerics could be a potential business opportunity for generic companies. The initial guidelines are expected to focus on erythropoietin, insulin, somatotropin and granulocyte-colony stimulating factor.
ACCESSION #
19983299

 

Related Articles

  • Generic makers are seeing promise in field of biotech engineering. Kirsche, Michelle L. // Drug Store News;2/16/2004, Vol. 26 Issue 2, p46 

    Reports that generic drug makers in the U.S. are seeing promise in the field of generic biologics. Scientific and economic debate over generic biologics; Efforts to create a scientific and regulatory framework for generic biologics; Predicted strong performance n the sector again in 2004;...

  • Economía de los medicamentos genéricos en América Latina. Tobar, Federico // Revista Panamericana de Salud Publica;Jan2008, Vol. 23 Issue 1, p59 

    In terms of economics, implementing generic drug policy is nothing other than consolidating (or even, creating) drug markets that set competitive prices, the result of which favors public access to essential drugs. This article approaches the topic of generic drugs from the economic perspective...

  • THE HATCH-WAXMAN ACT AND MARKET EXCLUSIVITY FOR GENERIC DRUG MANUFACTURERS: AN ENTITLEMENT OR AN INCENTIVE? Mehl, Ashlee B. // Chicago-Kent Law Review;2006, Vol. 81 Issue 2, p649 

    One of Congress' central goals in enacting the Hatch-Waxman Act was to expedite and encourage earlier market entry for generic pharmaceutical products. The Act provides that a generic firm may challenge a drug patent during its term by filing paperwork with the FDA that alleges either that its...

  • Generics enter 'Golden Age,' but hurdles remain. Baltazar, Amanda // Drug Store News;8/13/2007, Vol. 29 Issue 10, p87 

    The article focuses on the challenges faced by generic drug manufacturers despite the growing opportunities presented to them by patent expirations of drugs manufactured by big firms in the U.S. One outcome of the opportunities for generic drug makers is a diminishing number of firms in the U.S....

  • Top Generic-Drug Firms Go Into Branded. DAVID SAITO-CHUNG // Investors Business Daily;10/7/2014, pB06 

    In the past, it was easy to separate the ethical-drug makers that marketed proprietary medicines and the generics makers that specialized in making copies of such branded medicines.

  • Manufacturing of Biopharmaceuticals and Implications for Biosimilars. Wurm, Florian M. // Kidney & Blood Pressure Research;Jul2007, Vol. 30 Issue S1, p6 

    The article discusses the manufacturing of biopharmaceuticals and its implications for biosimilars. Biosimilars are not definable as identical molecules and thus they can never be made into generic drugs. The biological uncertainty principle is represented by biologicals and the diversity of...

  • Generic growth eases.  // Pharmaceutical Representative;Jan2009, Vol. 39 Issue 1, p7 

    The article reports on the performance of generic drugs in the global market for 2008. The sales for generic drugs in the global market have slowed down from 11.4% in 2007 to 3.6% in September. In the U.S., sales for generic drugs have increased by 2.7%, however, the total sales of the U.S....

  • A dose by any other name would not sell as sweet. Stepney, Rob // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;12/18/2010, Vol. 341 Issue 7786, p1316 

    The author examines why letters z and x achieved a remarkable and unexplained popularity in the branding of drugs based on the "British National Formulary" (BNF) from 1986 to 2004. It says that more than a fifth of the 1436 products added to the BNF between 1986 and 2005 had names that began...

  • Report from: Romania. Campos-Seijo, Bibiana // Pharmaceutical Technology;Feb2009, Vol. 33 Issue 2, p18 

    The article highlights the pharmaceutical industry of Romania. It mentions that analysts predict that the country will become the third largest generic drug manufacturing in the Eastern and Central Europe by 2015. It is observed that between June 2007 and June 2008, the Romanian pharmaceutical...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics